Neural Therapeutics Inc. · CSE:NURL
Neural Therapeutics — Investor Presentation (November 2022)
28 slides from Neural Therapeutics's investor presentation, November 2022
Slide 1: Neural Therapeutics Inc. Corporate Presentation
Neural Therapeutics Inc. Corporate Presentation November 2022
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements CONFIDENTIAL INFORMATION NOT AN OFFER This presentation (the “Presentation"), inclusive of all materials and information provided herewith This Presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any s
Slide 3: Disclaimer and Forward-Looking Statements (cont.)
Disclaimer and Forward-Looking Statements (cont.) FORWARD LOOKING STATEMENT AND RISK FACTORS Certain statements contained in this Presentation relate to the historical experience of our founders, management team This Presentation includes certain “forward-looking information” and “forward-looking st
Slide 4: Executive Overview
Executive Overview • Neural Therapeutics Inc. is an ethnobotanical drug-discovery/development company focused on developing products and conducting research with psychoactive plants. The first being San Pedro (Echinopsis pachanoi or Trichocereus pachanoi), a cactus containing mescaline. • Scientific
Slide 5: Market Stats - Pharmaceutical
Market Stats - Pharmaceutical We are targeting a potentially $70+ billion target market. Institutional Market Momentum ADHD: $29.6 Billion Anti-Addiction: $6.1 Billion Anxiety: $10.9 Billion Smoking Cessation: $23.4 Billion • Veterans of War & Heroic Hearts Project: are 2 examples Substance Abuse De
Slide 6: Market Stats - Nutraceutical
Market Stats - Nutraceutical We are targeting a potentially $175+ billion target market. ❖ Clinical Proof: Recently, cacti fiber was clinically proven to Weight Loss Supplements: $24 Billion Dietary Supplements: $140 Billion scavenge dietary fat and reduce obesity in separate studies ❖ Benefits: Cac
Slide 7: San Pedro Derived Mescaline Today – North America
San Pedro Derived Mescaline Today – North America A trend to relax laws regarding psychedelics to reduce epidemic street drug trends and provide a pathway to therapeutics. Decriminalization/Legalization/Regulation in North America San Pedro-Mescaline and Psychedelics in the US British Columbia (Vanc
Slide 8: Neural Therapeutics Advantage
Neural Therapeutics Advantage We are undertaking a holistic approach to respect the traditional use of the plant. Used Throughout History: Mescaline has been used for at least 5,700 years(1) ingested from cacti throughout North America Safety: Mescaline requires larger masses to achieve hallucinogen
Slide 9: Neural Therapeutics Philosophy
Neural Therapeutics Philosophy Why we are focusing on mescaline from natural sources, in particular the San Pedro cactus? Mescaline is Different Honoring Ethnobotanical Use ❖ Mescaline has a unique receptor drug affinity and response than ❖ Thousands of years of native experience is an invaluable so
Slide 10: History of Mescaline
History of Mescaline Mescaline has been widely used throughout our history. Mescaline is found in the fast- Dr. John Raleigh Briggs wrote German pharmacologist and physicist Failure of Mescaline to solve the growing San Pedro cactus and the about his experience after eating Arthur Heffter isolated t
Slide 11: About Psychedelic Cacti
About Psychedelic Cacti Native populations have used botanical medicines such as Peyote and San Pedro for millennia. Contains the highest concentration of Mescaline – around 3 to 6% of Despite the lower mescaline the dried weight concentration at around 1 - 4.5%, San Pedro Cactus the larger mass (si
Slide 12: Why we are focusing on plant sourced mescaline
Why we are focusing on plant sourced mescaline The advantages of natural sourced materials, in particular the San Pedro cactus Mescaline is Safer ❖ We believe Mescaline is safer when compared to other psychedelics – Greater masses are required reducing the chance of over-dose due to weighing errors
Slide 13: Mescaline vs. Other Psychedelics
Mescaline vs. Other Psychedelics Psychedelic Molecular Typical Duration of Potential Therapeutic Uses Onset of Effects Substance Structure Hallucination Dose Effects Addiction (e.g., alcohol), Anxiety LSD 0.05 - 0.2 mg 30 - 40 min 8 - 12h associated with terminal illness Addiction (tobacco, alcohol)
Slide 14: Why focus on Peru?
Why focus on Peru? Peru offers easier and broader access to the San Pedro plant and other similar species. Supply Chain: ❖ San Pedro is a native, hardy, plant and readily grows in the Northern Peru areas. There is no shortage of materials ❖ There is a great deal of variability of mescaline concentra
Slide 15: Research and Development Pathway
Research and Development Pathway Pharmaceutical Development • Goal: Is to develop efficacy of compounds that will satisfy the US- FDA requirements for drug-development Supply Chain Permits and Studies • Intellectual Property Protection: The Company will file patent applications on processes and, whe
Slide 16: R&D Targeted Near-Term Objectives – Common to Pharmaceutical and Nutraceutical
R&D Targeted Near-Term Objectives – Common to Pharmaceutical and Nutraceutical Our aim is to strategically identify and take advantage of an understudied area of the psychedelic market in key steps. Supply Chain: Identify a cGMP/CMC Supply Chain ensuring high quality starting materials a processes t
Slide 17: Pharmaceutical Market Strategy
Pharmaceutical Market Strategy The pharmaceutical strategy will focus on monetizing the mescaline containing portion of the cactus. ❖ Aim: To obtain insight into potential efficacy of the compounds that may be applied to the Pharmaceutical and Nutraceutical markets. Our goals are not dependent upon
Slide 18: R&D Targeted Deliverables Objectives - Pharmaceutical
R&D Targeted Deliverables Objectives - Pharmaceutical Our aim is to strategically identify and take advantage of an understudied area of the psychedelic market in key steps. Step 1a – Firm-up Path to Market and Conduct Fundamental Research Studies: ❖ Dosage: Identify the optimal safe therapeutic dos
Slide 19: Nutraceutical Market Strategy
Nutraceutical Market Strategy The nutraceutical strategy will focus on monetizing the non-mescaline portion of the cactus. Mescaline is not equally distributed throughout San Pedro. It resides mainly in the outer surfaces. Our focus will be to efficiently extract mescaline and other medically benefi
Slide 20: R&D Targeted Deliverables Objectives - Nutraceutical
R&D Targeted Deliverables Objectives - Nutraceutical Focus on extracting benefit from all parts of the cactus plant. ❖ Raw Material: The residual San Pedro solids and extracts separated from mescaline are the raw materials – determine the composition of the parts that have potential therapeutic bene
Slide 21: Past Milestones & Recent Developments
Past Milestones & Recent Developments Company Acquisition by CRO engaged for Comprehensive Engaged Additional CROs Peru is selected as the Identify New Management Successfully Formed. Nutritional High initial North Mescaline Research regulatory and legal advisors location of focus of the sources of
Slide 22: US Public Market Comparables
US Public Market Comparables Mescaline is an emerging focus on pubcos; NT’s value proposition has compelling upside potential Market Capitalization Company Exchange Ticker 1 (USD $MM) GH Research PLC NASDAQ GHRS $821 COMPASS Pathways PLC NASDAQ CMPS $771 Atai Life Sciences N.V. NASDAQ ATAI $733 Mind
Slide 23: Legality of San Pedro Globally
Legality of San Pedro Globally Unlike Peyote, possession of the San Pedro cactus is legal in most parts of the world. Peru: sold freely and widely as an ornamental purposes. Religious, traditional and folklore use is permitted in some circumstances; mescaline is category IB Overview controlled subst
Slide 24: Scientific & Impact Advisory Committee
Scientific & Impact Advisory Committee Professor David Nutt – David Nutt is a psychiatrist and the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Imperial College London. He was previously President of the, European Brain Council, British Association of Psycho
Slide 25: Leadership Team
Leadership Team Ian Campbell, MSc – Chief Executive Officer and Director – Mr. Campbell is an executive leader who has an international reputation for building effective teams, managing operations and product commercialization. He has managed multinational entities residing in the US, Canada as well
Slide 26: Contact Information
Contact Information Ian Campbell, CEO Neural Therapeutics Inc. C: 226-218-2255 E: icampbell@neuraltherapeutics.com 77 King Street West, Suite 2905 Toronto, ON M5K 1H1 28
Slide 27: Appendix: Sources – Market Statistics
Appendix: Sources – Market Statistics Pharmaceutical • ADHD: ADHD Therapeutics Market Size, Trends & Growth | 2021 to 2026 (marketdataforecast.com) • Anti-addiction: Addiction Treatment Market Size is Projected to Reach US$ 11 Billion by 2027 – The Market Publicist • Anxiety: Anxiety Disorders and D
Slide 28: Appendix: Additional Sources
Appendix: Additional Sources Market Statistics – Nutraceutical • Dietary Fat Uptake Reduction: https://pubmed.ncbi.nlm.nih.gov/25067985 • Diabetic Control Benefits of Cacti: Antidiabetic Effect of Fresh Nopal (Opuntia ficus-indica) in Low-Dose Streptozotocin-Induced Diabetic Rats Fed a High-Fat Diet
Neural Therapeutics — Investor Presentation (November 2022) on 6ix